FDA lifts hold on Cel-Sci's clinical trial for head and neck cancer drug

The U.S. Food and Drug Administration lifted a partial hold it placed nearly a year ago on a clinical trial for a head and neck cancer drug from Vienna-based Cel-Sci Corp. The company announced Monday morning it has received the go-ahead to resume the phase 3 clinical trial of immunotherapy drug Multikine. Cel-Sci had brought on 926 patients out of a desired 1,273 when the hold was put in place in September. The FDA instituted the hold because of an unreasonable an d significant risk of illness…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news